Last reviewed · How we verify

Full-Spectrum Cannabidiol

Staci Gruber, Ph.D. · Phase 2 active Small molecule

Full-Spectrum Cannabidiol is a Cannabinoid Small molecule drug developed by Staci Gruber, Ph.D.. It is currently in Phase 2 development for Epilepsy, Anxiety.

Cannabidiol acts as a CB1 receptor antagonist

Cannabidiol acts as a CB1 receptor antagonist Used for Epilepsy, Anxiety.

Likelihood of approval
12.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • CNS / neurology attrition -3.0pp
    CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034 —
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameFull-Spectrum Cannabidiol
SponsorStaci Gruber, Ph.D.
Drug classCannabinoid
TargetCB1 receptor
ModalitySmall molecule
Therapeutic areaNeurology
PhasePhase 2

Mechanism of action

Cannabidiol is a non-psychoactive compound found in cannabis that has been shown to have anxiolytic and antipsychotic effects through its action as a CB1 receptor antagonist.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Full-Spectrum Cannabidiol

What is Full-Spectrum Cannabidiol?

Full-Spectrum Cannabidiol is a Cannabinoid drug developed by Staci Gruber, Ph.D., indicated for Epilepsy, Anxiety.

How does Full-Spectrum Cannabidiol work?

Cannabidiol acts as a CB1 receptor antagonist

What is Full-Spectrum Cannabidiol used for?

Full-Spectrum Cannabidiol is indicated for Epilepsy, Anxiety.

Who makes Full-Spectrum Cannabidiol?

Full-Spectrum Cannabidiol is developed by Staci Gruber, Ph.D. (see full Staci Gruber, Ph.D. pipeline at /company/staci-gruber-ph-d).

What drug class is Full-Spectrum Cannabidiol in?

Full-Spectrum Cannabidiol belongs to the Cannabinoid class. See all Cannabinoid drugs at /class/cannabinoid.

What development phase is Full-Spectrum Cannabidiol in?

Full-Spectrum Cannabidiol is in Phase 2.

What are the side effects of Full-Spectrum Cannabidiol?

Common side effects of Full-Spectrum Cannabidiol include Dizziness, Somnolence, Nausea.

What does Full-Spectrum Cannabidiol target?

Full-Spectrum Cannabidiol targets CB1 receptor and is a Cannabinoid.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing